We are Dedicated

To advancing AF treatment through focusing on three main areas: innovating new technology solutions, investing in research and publications to advance clinical understanding and improving education and awareness of AF among clinicians and the general public.



For over 20 years, we have been deeply committed to delivering innovative solutions designed to help clinicians reach more patients and heal more hearts.


Research & Publications

With approximately 150 electrophysiology centres globally and a heritage of pioneering treatment in the field of EP, we are committed to advancing quality of care.


Education & Awareness

We enable lifelong learning for those on the frontlines of care at J&J Institute and strive to deliver AF education and awareness among clinicians and the general public.

Inspired by Our Patients 115563-190530

Meet Ipke, who believes that “it's everyone’s right to live atrial fibrillation-free"

On a Mission to Cure Atrial Fibrillation, innovation is at the heart of our organization and embedded in all we do. It fuels our discovery and development of new products and also extends to our collaborations, education and community efforts to bring new solutions to those in need. 

Are you aware of the different treatment options for AF patients? Make sure to discuss them with your doctor.

Clinical Evidence

VISTAX Prospective, Multicenter, Nonrandomized Study

VISTAX Prospective, Multicenter, Nonrandomized Study1

PRECEPT Prospective, Multicenter, Nonrandomized Study

PRECEPT Prospective, Multicenter, Nonrandomized Study2

ATTEST Prospective, Multicenter, Randomized Controlled Study

ATTEST Prospective, Multicenter, Randomized Controlled Study3

More Clinical Evidence

More Clinical Evidence 

Atrial Fibrillation – New Millennium Epidemic NEW 092810-190815

AF is the new millennium epidemic that affects millions of lives, mostly affecting the middle-aged and elderly. Watch this video to understand the full scope of the burden of the disease. 



Contact Us


  1. Duytschaever, M. et al. Standardized pulmonary vein isolation workflow to enclose veins with contiguous lesions: the multicentre VISTAX trial. Europace.2020;0, 1–8. doi:10.1093/europace/euaa157.
  2. Mansour M, Calkins H, Osorio J, et al. Persistent atrial fibrillation ablation with a contact force sensing radiofrequency catheter: the prospective multicenter PRECEPT trial. J Am Coll Cardiolol EP 2020;6:958-69.
  3.  Kuck, KH. et al. Catheter ablation or medical therapy to delay progression of atrial fibrillation: the randomized controlled atrial fibrillation progression trial (ATTEST). Europace.2020;00, 1–8. doi:10.1093/europace/euaa298.

Always verify catheter tip location using fluoroscopy or IC signals and consult the CARTO® 3 System User Guide regarding recommendations for fluoroscopy use.

Pellegrino, P.L., Brunetti, N.D., Gravina, D., Sacchetta, D., De Sanctis, V., Panigada, S., Di Biase, L., Di Biase, M., and Mantica, M. (2013). Nonfluoroscopic mapping reduces radiation exposure in ablation of atrial fibrillation. Journal of cardiovascular medicine 14, 528-533.
Earley, M.J., Showkathali, R., Alzetani, M., Kistler, P.M., Gupta, D., Abrams, D.J., Horrocks, J.A., Harris, S.J., Sporton, S.C., and Schilling, R.J. (2006). Radiofrequency ablation of arrhythmias guided by non-fluoroscopic catheter location: a prospective randomized trial. Eur Heart J 27, 1223-1229.    

Do not use excessive force to advance or withdraw the catheter when resistance is encountered. Careful catheter manipulation must be performed in order to avoid cardiac damage, perforation, or tamponade.

Product availability may differ in each country. Please contact us to find out further information.

Third party trademarks used herein are trademarks of their respective owners.

For full product details and precautions, please consult the IFU.

This publication is not intended for distribution outside of the EMEA region.

This site is published by Johnson & Johnson Medical NV/SA which is solely responsible for its content.

The minimum age for the website is 18. This site is intended for Healthcare Professionals from Europe, Middle-East and Africa where English is accepted in accordance with local laws and regulations, if applicable.

Important Information: Prior to use, refer to the “instructions for use” supplied with these devices for indications, contraindications, side effects, suggested procedure, warnings and precautions. As part of the Biosense Webster policy of continuous product development we reserve the right to change product specifications without prior notification.

This publication is not intended for distribution outside of the EMEA region.

EMEA 127436-211222